Answers are grounded in this paper and cite their sources.
Stroke is a leading cause of death and disability worldwide, and ischemic stroke is its most common subtype. Cerebral ischemia-reperfusion injury (CIRI) involves oxidative stress, inflammation and blood-brain barrier disruption, making mitochondrial quality control and regulated cell death important targets for mechanistic research. This review examines mitophagy, ferroptosis and emerging evidence for cuproptosis within a mitochondrial framework, while distinguishing established mechanisms from model-dependent findings and untested hypotheses. Ferroptosis is supported by substantial experimental evidence in stroke. Thrombin–ACSL4 signaling and NCOA4-mediated ferritinophagy can promote lipid peroxidation and iron dysregulation, respectively, whereas the system Xc – /GSH/GPX4 axis counteracts ferroptosis by supporting lipid-hydroperoxide detoxification. FSP1–CoQ10, DHODH–CoQ10 and GCH1–BH4 provide additional antioxidant mechanisms, although their stroke-specific contributions remain incompletely defined. Mitophagy operates through PINK1/Parkin, BNIP3/NIX and FUNDC1 pathways and can have protective or detrimental effects depending on pathway activity, lysosomal function and mitochondrial reserve. Experimental studies support selected connections between mitochondrial quality control and ferroptosis, but proposed competition between mitophagy and ferritinophagy remains unverified. Itaconate-mediated GPX4 alkylation and IRG1-associated mitophagy represent distinct mechanisms reported in different hemorrhagic stroke models. In contrast, copper-homeostasis changes and FDX1 perturbation in ischemic models do not establish the complete cuproptosis mechanism. We therefore distinguish copper/FDX1 intervention evidence, bioinformatic associations and contextual mechanistic clues. A possible mitophagy–cuproptosis tolerance relationship is presented as a testable hypothesis whose selective recognition signals, receptors and quantitative requirements remain unresolved. Therapeutic timing is discussed conceptually without fixed intervention windows. Future progress requires mechanism-specific assays, time-resolved mitophagic flux measurements, genetic rescue and validation across relevant brain cell types and clinically representative models.
No takes yet. Share an insight, caveat, or question.
Shi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: